1

Dr Emil Bujak

Emil Bujak

Investment Professional - Advisor to HBM Partners

Over ten years of experience in venture capital and medicinal research. Prior experience as a registered pharmacist, and in antibody technology research at Philogen. Holds a PhD and an MSc in Medicinal and Industrial Pharmaceutical Sciences from ETH Zurich and is a Chartered Financial Analyst (CFA) since 2019. Board member of Polyneuron, board observer at Pyxis Oncology.

 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171